Gain access now
Download the latest drug budget forecasts and market insights to inform your pharmacy planning
Utilize actionable insights from our new report.
0.00
%
Projected overall drug price inflation rate for July 1, 2023 – June 30, 2024
The challenges that have impacted health systems in the wake of the pandemic require pharmacy leaders to build upon current strengths and expand their acute and non-acute strategies for 2023 and beyond.
Steven Lucio, PharmD, BCPS
Sr. Principal, Vizient Center for Pharmacy Practice Excellence
-
5
Top spend drugs: Adalimumab, Pembrolizumab, Ustekinumab, Immune globulin intravenous, Remdesivir
-
7
Biosimilar competition for Humira (adalimumab) is here – seven approved, more on the way
-
63-fold
The increase in telehealth visits in Medicare patients during the pandemic
-
10%
Expected growth for home healthcare over the next five years
-
6 of 10
Six of the top 10 medications for non-acute spend are in autoimmune inflammatory conditions
-
4.33%
Projected inflation rate for specialty drugs
Want additional resources?
Vizient Pharmacy program participants have access to additional resources including price change projections at the individual medication level
Not already enjoying Vizient Pharmacy program benefits?
Learn how to access now